AstraZeneca beats quarterly estimates, maintains forecasts

Pharma blue-chip AstraZeneca on Friday topped analysts' expectations for first-quarter profit and stood by its forecasts for 2022, as newer therapies for cancer, kidney disease, and rare conditions made up for a decline in COVID-19 vaccine sales.